oxonic acid has been researched along with Disease Models, Animal in 79 studies
Oxonic Acid: Antagonist of urate oxidase.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 8.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "The study was designed to explore the effects of Withaferin A (WFA) on hyperuricemia-induced kidney injury and its action mechanism." | 8.02 | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms. ( Bai, Y; Li, P; Ru, J; Tang, L; Wang, J; Zhao, X, 2021) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 8.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 7.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "01) effectiveness of A-MNPs in management of hyperuricemic nephrolithiasis was observed through estimating pH and uric acid levels in urine and serum samples of mice." | 7.91 | Targeting kidneys by superparamagnetic allopurinol loaded chitosan coated nanoparticles for the treatment of hyperuricemic nephrolithiasis. ( Bhatt, DC; Jindal, DK; Kandav, G, 2019) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 7.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| "The purpose of this study was to test the effect of allopurinol (AP) and sodium bicarbonate on the kidney injury induced by recurrent heat stress dehydration with concomitant repeated episodes of rhabdomyolysis." | 7.88 | Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. ( Blas-Marron, MG; García-Arroyo, FE; Glaser, J; Gonzaga, G; Johnson, RJ; Madero, M; Muñoz-Jimenez, I; Osorio-Alonso, H; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Silverio, O; Tapia, E; Weiss, I, 2018) |
| "In hyperuricemia rats, both 25 and 50mg/kg of oral Dioscin decreased serum uric acid levels over 4h." | 7.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 7.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| "We tested whether melamine nephrotoxicity was exacerbated by urate (a typical component of renal stones in humans) in rats with hyperuricemiainduced by the uricase inhibitor, potassium oxonate (Oxo)." | 7.81 | Melamine Nephrotoxicity is Mediated by Hyperuricemia. ( Li, HT; Liu, JM; Trachtman, H; Trasande, L; Wang, LL; Wang, PX; Zhang, L, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 7.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "Arginine transport was significantly decreased in hyperuricemia." | 7.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "The effect of febuxostat (Fx), a non-purine and selective xanthine oxidase inhibitor, on glomerular microcirculatory changes in 5/6 nephrectomy (5/6 Nx) Wistar rats with and without oxonic acid (OA)-induced hyperuricemia was evaluated." | 7.74 | Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L, 2008) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 7.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 7.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 5.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Although hyperuricemia has been shown to be associated with the progression of cardiovascular disorder and chronic kidney disease (CKD), there is conflicting evidence as to whether xanthine oxidase (XO) inhibitors confer organ protection besides lowering serum urate levels." | 5.56 | Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. ( Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 5.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "The anti-hyperuricemic bioactivity of the non-alkaloids fraction and compounds were evaluated with potassium oxonate (PO) induced hyperuricemia mice model in vivo, and monosodium urate (MSU) induced human renal tubular epithelial cells (HK-2) was selected to test in vitro, respectively, with benzobromarone as the positive control." | 4.12 | Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro. ( Hu, BY; Luo, XD; Ma, DY; Xiang, ML; Zhao, LX; Zhao, YL, 2022) |
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 4.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "The study was designed to explore the effects of Withaferin A (WFA) on hyperuricemia-induced kidney injury and its action mechanism." | 4.02 | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms. ( Bai, Y; Li, P; Ru, J; Tang, L; Wang, J; Zhao, X, 2021) |
| "Hyperuricemia is defined by the European Rheumatology Society as a uric acid level greater than 6 mg/dl (60 mg/l or 360 μmol/l)." | 4.02 | Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance. ( Affes, H; Charfi, S; Dhouibi, R; Hammami, S; Jamoussi, K; Ksouda, K; Marekchi, R; Moalla, D; Sahnoun, Z; Salem, MB; Zeghal, KM, 2021) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 4.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 3.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| "01) effectiveness of A-MNPs in management of hyperuricemic nephrolithiasis was observed through estimating pH and uric acid levels in urine and serum samples of mice." | 3.91 | Targeting kidneys by superparamagnetic allopurinol loaded chitosan coated nanoparticles for the treatment of hyperuricemic nephrolithiasis. ( Bhatt, DC; Jindal, DK; Kandav, G, 2019) |
| "5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
| "With co-treatment of potassium oxonate (PO) and xanthine sodium salt (XSS), a zebrafish larva model of acute hyperuricemia has been constructed for the first time." | 3.91 | A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity. ( Li, Q; Wang, F; Xing, C; Zhang, Y, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 3.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| "In hyperuricemia rats, both 25 and 50mg/kg of oral Dioscin decreased serum uric acid levels over 4h." | 3.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "The purpose of this study was to test the effect of allopurinol (AP) and sodium bicarbonate on the kidney injury induced by recurrent heat stress dehydration with concomitant repeated episodes of rhabdomyolysis." | 3.88 | Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. ( Blas-Marron, MG; García-Arroyo, FE; Glaser, J; Gonzaga, G; Johnson, RJ; Madero, M; Muñoz-Jimenez, I; Osorio-Alonso, H; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Silverio, O; Tapia, E; Weiss, I, 2018) |
| "Benzbromarone (BBR) is effective in the treatment of gout; however, clinical findings have shown it can also cause fatal hepatic failure." | 3.85 | Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity. ( Lan, Q; Pang, J; Peng, Y; Wang, H; Wang, S; Wang, W; Wang, X; Zhang, T; Zhao, H; Zhao, Y; Zheng, J, 2017) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 3.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| " affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
| "We tested whether melamine nephrotoxicity was exacerbated by urate (a typical component of renal stones in humans) in rats with hyperuricemiainduced by the uricase inhibitor, potassium oxonate (Oxo)." | 3.81 | Melamine Nephrotoxicity is Mediated by Hyperuricemia. ( Li, HT; Liu, JM; Trachtman, H; Trasande, L; Wang, LL; Wang, PX; Zhang, L, 2015) |
| " oldhamii leaf extracts was investigated using potassium oxonate (PO)-induced acute hyperuricemia." | 3.81 | Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice. ( Chiu, CC; Chuang, HL; Ho, ST; Huang, CC; Lin, CY; Lin, LC; Liu, YL; Tung, YT; Wu, JH, 2015) |
| "This study evaluated the effects of crude drugs obtained from the silkworm in mice with oxonic acid-induced hyperuricemia using xanthine oxidase inhibitory activity and plasma uric acid levels." | 3.81 | [The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice]. ( Minakuchi, N; Miyata, Y; Murakami, A; Sakazaki, F; Tanaka, R, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 3.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "These results suggest that pallidifloside D possesses a potent uricosuric effect in hyperuricemic mice through decreasing renal mURAT1 and GLUT9, which contribute to the enhancement of uric acid excretion and attenuate hyperuricemia-induced renal dysfunction." | 3.80 | Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. ( Ruan, JL; Wang, SQ; Wu, XH; Zhang, J; Zhang, YW, 2014) |
| " d-1 ) to prepare the hyperuricemia model, and divided into normal, model, Allopurinol, LE high dosage, middle dosage and low dose (200, 100, 50 mg ." | 3.80 | [Regulatory effect of leonurus extracts on hyperuricemia in rats]. ( An, YT; Li, J; Wang, T; Wu, ZZ; Yan, M, 2014) |
| " riparia in reducing serum uric acid levels in a potassium oxonate-induced hyperuricemia mouse model." | 3.80 | Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout. ( Anderson, S; Wu, XH; Yu, CH; Zhang, CF; Zhang, YW, 2014) |
| "The hypouricemic actions of exopolysaccharide produced by Cordyceps militaris (EPCM) in potassium oxonate-induced hyperuricemia in mice were examined." | 3.80 | Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice. ( Gao, J; Ma, L; Yuan, Y; Zhang, S, 2014) |
| "Treatment with Jianpihuashi Decoction for 30 days, the serum uric acid level of rats with hyperuricemia were significantly decreased (P < 0." | 3.79 | [Effect of jianpihuashi decoction on rats with hyperuricemia]. ( Chen, JW; Guo, J; Jiang, JM; Li, C; Xue, ZY; Zhou, LY; Zhou, Y, 2013) |
| "These findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout." | 3.78 | Reducing effect of mangiferin on serum uric acid levels in mice. ( Gao, L; Li, L; Lin, H; Liu, X; Lu, W; Niu, Y, 2012) |
| "Arginine transport was significantly decreased in hyperuricemia." | 3.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 3.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "In rats with hyperuricemia induced by 2% oxonic acid and 0." | 3.74 | Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. ( Chen, K; Cui, WY; Liu, GS; Long, CL; Pan, ZY; Qin, XC; Wang, H; Zhang, YF, 2008) |
| "The effect of febuxostat (Fx), a non-purine and selective xanthine oxidase inhibitor, on glomerular microcirculatory changes in 5/6 nephrectomy (5/6 Nx) Wistar rats with and without oxonic acid (OA)-induced hyperuricemia was evaluated." | 3.74 | Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L, 2008) |
| " We evaluated the hypouricemic effect of propolis from China on hyperuricemia induced by the uricase inhibitor, oxonic acid (500 mg/kg p." | 3.73 | [Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats]. ( Nishioka, N; Tsuji, T; Yoshizumi, K, 2005) |
| "The effects of acacetin (1) and 4,5-O-dicaffeoylquinic acid methyl ester (2), compounds contained in the flowers of Chrysanthemum sinense SABINE, on the serum uric acid level were investigated using the rats pretreated with the uricase inhibitor potassium oxonate as an animal model for hyperuricemia." | 3.73 | Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats. ( Awale, S; Kadota, S; Matsumoto, K; Murakami, Y; Nguyen, MT; Shi, L; Tezuka, Y; Tran, QL; Ueda, JY; Zaidi, SF, 2005) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 3.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co." | 3.70 | Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999) |
| " The ideal uricase inhibitor for induction of hyperuricemia would be one which is irreversible, noncompetitive, and relatively nontoxic, so that its activity would be independent of high levels of uric acid, and effective inhibition could be attained at low dosage levels." | 2.36 | Use of the uricase-inhibited rat as an animal model in toxicology. ( Nera, EA; Stavric, B, 1978) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 1.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Gout is a crystalline-related arthropathy caused by the deposition of monosodium urate (MSU)." | 1.56 | Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. ( Ha, EH; Hu, Q; Li, H; Li, Z; Pang, J; Tian, S; Wang, W; Zhou, M, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 1.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "Although hyperuricemia has been shown to be associated with the progression of cardiovascular disorder and chronic kidney disease (CKD), there is conflicting evidence as to whether xanthine oxidase (XO) inhibitors confer organ protection besides lowering serum urate levels." | 1.56 | Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. ( Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M, 2020) |
| "sinensis) has been used to treat hyperuricemia and gout." | 1.48 | Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice. ( Barba, FJ; He, J; Li, S; Lorenzo, JM; Zhan, S; Zhang, R; Zhu, Z, 2018) |
| "Treatment with uric acid protected Caco-2 cells from indomethacin-induced oxidative stress, lipid peroxidation, and cytotoxicity." | 1.46 | Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. ( Furuhashi, H; Higashiyama, M; Hokari, R; Komoto, S; Kurihara, C; Maruta, K; Matsuo, H; Miura, S; Nagao, S; Narimatsu, K; Okada, Y; Sato, H; Shirakabe, K; Takajo, T; Tomita, K; Watanabe, C; Yasutake, Y; Yoshikawa, K, 2017) |
| "Although hyperuricemia is shown to accelerate chronic kidney disease, the mechanisms remain unclear." | 1.46 | Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. ( Asakawa, S; Hosoyamada, M; Kumagai, T; Morimoto, C; Nakamura, T; Shibata, S; Shiraishi, T; Tamura, Y; Uchida, S, 2017) |
| " However, the pharmacokinetic studies in rats showed that its oral bioavailability was only 1." | 1.43 | Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity. ( Feng, GH; Gao, LH; Li, L; Liu, HY; Liu, J; Liu, X; Niu, Y, 2016) |
| " To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model." | 1.36 | Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. ( Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T, 2010) |
| "Hyperuricemia was induced in Sprague-Dawley rats by administration of the uricase inhibitor, oxonic acid (750 mg/kg per day)." | 1.35 | Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Nakagawa, T; Rodríguez-Iturbe, B; Sánchez-Lozada, LG; Sautin, YY; Soto, V; Tapia, E, 2008) |
| "Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
| " These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring." | 1.31 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ( Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002) |
| "Thus, in acute renal failure, tubular functional impairments may recover at different rates." | 1.26 | Renal function in rats with acute medullary injury. ( Brown, EA; Finkelstein, FO; Hayslett, JP; Kliger, AS, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (8.86) | 18.7374 |
| 1990's | 2 (2.53) | 18.2507 |
| 2000's | 17 (21.52) | 29.6817 |
| 2010's | 40 (50.63) | 24.3611 |
| 2020's | 13 (16.46) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, G | 1 |
| Yu, Q | 1 |
| Xu, L | 1 |
| Huang, Z | 1 |
| Mai, L | 1 |
| Jiang, L | 1 |
| Su, Z | 1 |
| Xie, J | 1 |
| Li, Y | 2 |
| Liu, Y | 1 |
| Lin, Z | 1 |
| Chen, J | 1 |
| Hu, BY | 1 |
| Zhao, YL | 1 |
| Ma, DY | 1 |
| Xiang, ML | 1 |
| Zhao, LX | 1 |
| Luo, XD | 1 |
| Kandav, G | 1 |
| Bhatt, DC | 1 |
| Jindal, DK | 1 |
| Dera, AA | 1 |
| Rajagopalan, P | 1 |
| Alfhili, MA | 1 |
| Ahmed, I | 1 |
| Chandramoorthy, HC | 1 |
| Wang, W | 3 |
| Pang, J | 3 |
| Ha, EH | 1 |
| Zhou, M | 1 |
| Li, Z | 2 |
| Tian, S | 1 |
| Li, H | 1 |
| Hu, Q | 1 |
| Bilal, M | 1 |
| Ahmad, S | 1 |
| Rehman, T | 1 |
| Abbasi, WM | 1 |
| Ghauri, AO | 1 |
| Arshad, MA | 1 |
| Ayaz, S | 1 |
| Nawaz, A | 1 |
| Omizo, H | 1 |
| Tamura, Y | 2 |
| Morimoto, C | 2 |
| Ueno, M | 1 |
| Hayama, Y | 1 |
| Kuribayashi-Okuma, E | 1 |
| Uchida, S | 2 |
| Shibata, S | 2 |
| Han, B | 1 |
| Gong, M | 1 |
| Qiu, Y | 1 |
| Zou, Z | 1 |
| Wen, S | 1 |
| Wang, D | 1 |
| Yu, H | 2 |
| Liu, M | 1 |
| Chen, Q | 2 |
| Bao, R | 1 |
| Liu, L | 1 |
| Zhang, Y | 3 |
| Wang, T | 3 |
| Chen, Y | 2 |
| Zhao, Z | 1 |
| Yang, Y | 1 |
| Li, L | 3 |
| Jiang, Y | 1 |
| Lin, C | 1 |
| Cao, Y | 1 |
| Zhou, P | 1 |
| Tian, Y | 2 |
| Wu, T | 1 |
| Dhouibi, R | 1 |
| Affes, H | 1 |
| Salem, MB | 1 |
| Moalla, D | 1 |
| Marekchi, R | 1 |
| Charfi, S | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Jamoussi, K | 1 |
| Zeghal, KM | 1 |
| Ksouda, K | 1 |
| Lin, L | 1 |
| Zhao, M | 1 |
| Peng, A | 1 |
| Zhao, K | 1 |
| Zhao, X | 1 |
| Wang, J | 1 |
| Tang, L | 1 |
| Li, P | 1 |
| Ru, J | 1 |
| Bai, Y | 1 |
| Tian, J | 1 |
| Wang, B | 1 |
| Xie, B | 1 |
| Liu, X | 4 |
| Zhou, D | 1 |
| Hou, X | 1 |
| Xiang, L | 1 |
| Asakawa, S | 1 |
| Shiraishi, T | 1 |
| Nakamura, T | 1 |
| Kumagai, T | 1 |
| Hosoyamada, M | 1 |
| Zhang, HJ | 1 |
| Li, LN | 1 |
| Zhou, J | 1 |
| Yang, QQ | 1 |
| Liu, PG | 1 |
| Xu, P | 1 |
| Liang, WQ | 1 |
| Cheng, L | 1 |
| Zhang, YQ | 1 |
| Pu, JB | 1 |
| Hu, YJ | 1 |
| Wang, H | 2 |
| Peng, Y | 1 |
| Zhang, T | 1 |
| Lan, Q | 1 |
| Zhao, H | 1 |
| Zhao, Y | 1 |
| Wang, X | 1 |
| Wang, S | 1 |
| Zheng, J | 1 |
| Jin, L | 1 |
| Liu, J | 3 |
| Li, J | 3 |
| Nakashima, A | 1 |
| Yamauchi, A | 1 |
| Matsumoto, J | 1 |
| Dohgu, S | 1 |
| Takata, F | 1 |
| Koga, M | 1 |
| Fukae, J | 1 |
| Tsuboi, Y | 1 |
| Kataoka, Y | 1 |
| Zhang, R | 1 |
| Zhan, S | 2 |
| Li, S | 1 |
| Zhu, Z | 1 |
| He, J | 1 |
| Lorenzo, JM | 1 |
| Barba, FJ | 1 |
| Sánchez-Lozada, LG | 4 |
| García-Arroyo, FE | 2 |
| Gonzaga, G | 1 |
| Silverio, O | 1 |
| Blas-Marron, MG | 1 |
| Muñoz-Jimenez, I | 1 |
| Tapia, E | 5 |
| Osorio-Alonso, H | 1 |
| Madero, M | 2 |
| Roncal-Jiménez, CA | 1 |
| Weiss, I | 1 |
| Glaser, J | 1 |
| Johnson, RJ | 5 |
| Li, Q | 1 |
| Wang, F | 1 |
| Xing, C | 1 |
| Nishizawa, K | 1 |
| Yoda, N | 1 |
| Morokado, F | 1 |
| Komori, H | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
| Liang, G | 1 |
| Nie, Y | 1 |
| Chang, Y | 1 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Zheng, X | 1 |
| Xiao, D | 1 |
| Zheng, Q | 1 |
| Li, C | 2 |
| Duan, S | 1 |
| Yuan, X | 1 |
| Liang, J | 1 |
| Hou, S | 1 |
| Zhou, Z | 1 |
| Dong, Y | 1 |
| Zhou, H | 1 |
| Zhao, W | 1 |
| Ide, H | 1 |
| Kikuchi, E | 1 |
| Hasegawa, M | 1 |
| Hattori, S | 1 |
| Yasumizu, Y | 1 |
| Miyajima, A | 1 |
| Oya, M | 1 |
| Hou, SX | 1 |
| Zhu, WJ | 1 |
| Pang, MQ | 1 |
| Jeffry, J | 1 |
| Zhou, LL | 1 |
| Wu, XH | 4 |
| Yu, CH | 1 |
| Zhang, CF | 1 |
| Anderson, S | 2 |
| Zhang, YW | 4 |
| Chen, JW | 1 |
| Zhou, Y | 1 |
| Xue, ZY | 1 |
| Guo, J | 1 |
| Zhou, LY | 1 |
| Jiang, JM | 1 |
| Ma, L | 1 |
| Zhang, S | 1 |
| Yuan, Y | 1 |
| Gao, J | 1 |
| Wang, CZ | 1 |
| Zhang, J | 3 |
| Wang, SQ | 3 |
| Han, L | 1 |
| Yuan, CS | 1 |
| Ruan, JL | 1 |
| Kajiwara, T | 1 |
| Miura, K | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Komura, T | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shirasaka, T | 2 |
| Unno, M | 1 |
| Kurra, V | 2 |
| Vehmas, T | 1 |
| Eräranta, A | 2 |
| Jokihaara, J | 1 |
| Pirttiniemi, P | 1 |
| Ruskoaho, H | 1 |
| Tokola, H | 1 |
| Niemelä, O | 1 |
| Mustonen, J | 1 |
| Pörsti, I | 1 |
| Yan, M | 1 |
| An, YT | 1 |
| Wu, ZZ | 1 |
| Cristóbal-García, M | 1 |
| Osorio, H | 1 |
| Arellano-Buendía, AS | 1 |
| Rodríguez-Iturbe, B | 3 |
| Pedraza-Chaverrí, J | 1 |
| Correa, F | 1 |
| Zazueta, C | 1 |
| Lozada, LG | 1 |
| Hou, PY | 1 |
| Mi, C | 1 |
| He, Y | 1 |
| Yu, F | 1 |
| Tanaka, R | 1 |
| Miyata, Y | 1 |
| Minakuchi, N | 1 |
| Murakami, A | 1 |
| Sakazaki, F | 1 |
| Tung, YT | 1 |
| Lin, LC | 1 |
| Liu, YL | 1 |
| Ho, ST | 1 |
| Lin, CY | 1 |
| Chuang, HL | 1 |
| Chiu, CC | 1 |
| Huang, CC | 1 |
| Wu, JH | 1 |
| Zhang, L | 1 |
| Li, HT | 1 |
| Wang, LL | 1 |
| Trachtman, H | 1 |
| Trasande, L | 1 |
| Wang, PX | 1 |
| Liu, JM | 1 |
| Niu, Y | 2 |
| Liu, HY | 1 |
| Gao, LH | 1 |
| Feng, GH | 1 |
| Yoon, IS | 1 |
| Park, DH | 1 |
| Ki, SH | 1 |
| Cho, SS | 1 |
| Yasutake, Y | 1 |
| Tomita, K | 1 |
| Higashiyama, M | 1 |
| Furuhashi, H | 1 |
| Shirakabe, K | 1 |
| Takajo, T | 1 |
| Maruta, K | 1 |
| Sato, H | 1 |
| Narimatsu, K | 1 |
| Yoshikawa, K | 1 |
| Okada, Y | 1 |
| Kurihara, C | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Nagao, S | 1 |
| Matsuo, H | 1 |
| Miura, S | 1 |
| Hokari, R | 1 |
| Tang, DH | 1 |
| Ye, YS | 1 |
| Wang, CY | 1 |
| Li, ZL | 1 |
| Zheng, H | 1 |
| Ma, KL | 1 |
| Tahvanainen, AM | 1 |
| Vehmas, TI | 1 |
| Kööbi, P | 1 |
| Lakkisto, P | 1 |
| Tikkanen, I | 1 |
| Niemelä, OJ | 1 |
| Mustonen, JT | 1 |
| Pörsti, IH | 1 |
| Chen, R | 1 |
| Shang, Y | 1 |
| Jiao, B | 1 |
| Huang, C | 1 |
| Soto, V | 3 |
| Avila-Casado, C | 3 |
| Sautin, YY | 1 |
| Nakagawa, T | 2 |
| Franco, M | 3 |
| Long, CL | 1 |
| Qin, XC | 1 |
| Pan, ZY | 1 |
| Chen, K | 1 |
| Zhang, YF | 1 |
| Cui, WY | 1 |
| Liu, GS | 1 |
| Yanagihara, K | 1 |
| Tsumuraya, M | 1 |
| Takigahira, M | 1 |
| Mihara, K | 1 |
| Kubo, T | 1 |
| Ohuchi, K | 1 |
| Seyama, T | 1 |
| Doi, Y | 1 |
| Okada, T | 1 |
| Matsumoto, H | 1 |
| Ichihara, M | 1 |
| Ishida, T | 1 |
| Kiwada, H | 1 |
| Sadahiro, S | 1 |
| Suzuki, T | 1 |
| Maeda, Y | 1 |
| Tanaka, A | 1 |
| Okada, K | 1 |
| Kanoda, H | 1 |
| Kamijo, A | 1 |
| Schwartz, IF | 1 |
| Grupper, A | 2 |
| Chernichovski, T | 1 |
| Hillel, O | 1 |
| Engel, A | 1 |
| Schwartz, D | 1 |
| Hwa, KS | 1 |
| Chung, DM | 1 |
| Chung, YC | 1 |
| Chun, HK | 1 |
| Yi, LT | 1 |
| Su, DX | 1 |
| Dong, JF | 1 |
| Li, CF | 1 |
| Lu, W | 1 |
| Gao, L | 1 |
| Lin, H | 1 |
| Silva, CR | 1 |
| Fröhlich, JK | 1 |
| Oliveira, SM | 1 |
| Cabreira, TN | 1 |
| Rossato, MF | 1 |
| Trevisan, G | 1 |
| Froeder, AL | 1 |
| Bochi, GV | 1 |
| Moresco, RN | 1 |
| Athayde, ML | 1 |
| Ferreira, J | 1 |
| Ikeda, M | 1 |
| Furukawa, H | 1 |
| Imamura, H | 1 |
| Shimizu, J | 1 |
| Ishida, H | 1 |
| Masutani, S | 1 |
| Tatsuta, M | 1 |
| Kawasaki, T | 1 |
| Satomi, T | 1 |
| Santamaría, J | 1 |
| Herrera-Acosta, J | 1 |
| Mori, T | 3 |
| Fujiwara, Y | 3 |
| Yano, M | 3 |
| Tamura, S | 3 |
| Yasuda, T | 3 |
| Takiguchi, S | 3 |
| Monden, M | 3 |
| Wang, Y | 1 |
| Zhu, JX | 1 |
| Kong, LD | 1 |
| Yang, C | 1 |
| Cheng, CH | 1 |
| Zhang, X | 1 |
| Nukatsuka, M | 1 |
| Fujioka, A | 1 |
| Nakagawa, F | 2 |
| Oshimo, H | 1 |
| Kitazato, K | 1 |
| Uchida, J | 2 |
| Sugimoto, Y | 2 |
| Nagayama, S | 1 |
| Fukushima, M | 2 |
| Yoshizumi, K | 1 |
| Nishioka, N | 1 |
| Tsuji, T | 1 |
| Nguyen, MT | 1 |
| Awale, S | 1 |
| Tezuka, Y | 1 |
| Shi, L | 1 |
| Zaidi, SF | 1 |
| Ueda, JY | 1 |
| Tran, QL | 1 |
| Murakami, Y | 1 |
| Matsumoto, K | 1 |
| Kadota, S | 1 |
| Chen, GL | 1 |
| Wei, W | 1 |
| Xu, SY | 1 |
| Tsujimoto, H | 1 |
| Tsukioka, S | 1 |
| Koizumi, K | 1 |
| Oka, T | 1 |
| Watanabe, T | 1 |
| Wessale, JL | 1 |
| Zhao, L | 1 |
| Hirai, A | 1 |
| Kumagai, A | 1 |
| Brown, EA | 1 |
| Kliger, AS | 1 |
| Hayslett, JP | 1 |
| Finkelstein, FO | 1 |
| Dan, T | 1 |
| Yoneya, T | 1 |
| Onoma, M | 1 |
| Onuma, E | 1 |
| Ozawa, K | 1 |
| Cao, S | 1 |
| Lu, K | 1 |
| Tóth, K | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Nishimura, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Ikeda, Y | 1 |
| Taguchi, T | 1 |
| Nakamura, Y | 1 |
| Hirose, F | 1 |
| Tsukuda, M | 1 |
| Musil, J | 1 |
| Stavric, B | 1 |
| Nera, EA | 1 |
| Newburger, J | 1 |
| Hsu, TF | 1 |
| Combs, AB | 1 |
| Winocour, PD | 1 |
| Munday, KA | 1 |
| Taylor, TG | 1 |
| Tuner, MR | 1 |
| Bluestone, R | 1 |
| Waisman, J | 1 |
| Klinenberg, JR | 1 |
2 reviews available for oxonic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Animal model for gout].
Topics: Animals; Chickens; Disease Models, Animal; Female; Gout; Male; Mice; Oxonic Acid; Poultry Diseases; | 1982 |
Use of the uricase-inhibited rat as an animal model in toxicology.
Topics: Aggression; Animals; Diet; Disease Models, Animal; Dogs; Embryo, Mammalian; Female; Gout; Humans; Ki | 1978 |
77 other studies available for oxonic acid and Disease Models, Animal
| Article | Year |
|---|---|
Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Berberine; Blood Urea Nitrogen; Ch | 2021 |
Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro.
Topics: Alstonia; Animals; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hype | 2022 |
Targeting kidneys by superparamagnetic allopurinol loaded chitosan coated nanoparticles for the treatment of hyperuricemic nephrolithiasis.
Topics: Administration, Oral; Allopurinol; Animals; Chemical Precipitation; Chitosan; Disease Models, Animal | 2019 |
Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats.
Topics: Animals; Benzoquinones; Disease Models, Animal; Hyperuricemia; Kidney; Kidney Diseases; Male; Mitoch | 2020 |
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Topics: Animals; Benzimidazoles; Benzoxazoles; Cell Line; Disease Models, Animal; Gout; Humans; Hyperuricemi | 2020 |
Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Drug Developmen | 2020 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseas | 2020 |
NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; | 2020 |
The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine.
Topics: Adenine; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromatography, High Pres | 2020 |
Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Topics: Animals; Antioxidants; Disease Models, Animal; Enzyme Inhibitors; Flavanones; Glucose Transport Prot | 2021 |
Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance.
Topics: Animals; Antioxidants; Biomarkers; Chronic Disease; Creatinine; Disease Models, Animal; Hyperuricemi | 2021 |
Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides.
Topics: Animals; Creatinine; Disease Models, Animal; Flavonoids; Gout Suppressants; Hyperuricemia; Malondial | 2021 |
Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms.
Topics: Animals; Apoptosis; Disease Models, Animal; Fibrosis; Hyperuricemia; Kidney; Kidney Diseases; Male; | 2021 |
Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Creatinine; Cytokines; Disease Models, Animal; Disulfiram; Humans; Mice; | 2022 |
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Albuminuria; Animals; Blood Pressure; Cyclic N-Oxides; Deoxygua | 2017 |
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity.
Topics: Activation, Metabolic; Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Cytochrome P- | 2017 |
Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Topics: Adenine; Animals; Biomarkers; Creatinine; Dioscorea; Diosgenin; Disease Models, Animal; Dose-Respons | 2018 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice.
Topics: Animals; Creatinine; Disease Models, Animal; Fruit; Gene Expression Regulation; Hyperuricemia; Liver | 2018 |
Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate.
Topics: Acute Kidney Injury; Allopurinol; Animals; Disease Models, Animal; Disease Progression; Glycerol; He | 2018 |
A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity.
Topics: Allopurinol; Animals; Anserine; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughpu | 2019 |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Topics: Adenine; Animals; Antiporters; Cephalexin; Creatinine; Disease Models, Animal; Down-Regulation; Huma | 2019 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Curcumin; Cytokines; Dis | 2019 |
MiR-143-3p directly targets GLUT9 to reduce uric acid reabsorption and inflammatory response of renal tubular epithelial cells.
Topics: Animals; Base Sequence; Case-Control Studies; Chemokine CCL2; Disease Models, Animal; Gene Expressio | 2019 |
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2013 |
Protective effect of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats induced by yeast and potassium oxonate.
Topics: Animals; Base Sequence; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; DNA Primers; Hypert | 2014 |
Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Hy | 2014 |
[Effect of jianpihuashi decoction on rats with hyperuricemia].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drug Combinations; Dr | 2013 |
Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Antimetabolites; Cordyceps; Disease Models, Animal; Hyperuricemia; Liver; Mice; Oxonic Acid | 2014 |
Effects of Smilaxchinoside A and Smilaxchinoside C, two steroidal glycosides from Smilax riparia, on hyperuricemia in a mouse model.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Glucose Transport Proteins, Facilitative; Gl | 2014 |
Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Glucose Transpor | 2014 |
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; G | 2015 |
Effects of oxonic acid-induced hyperuricemia on mesenteric artery tone and cardiac load in experimental renal insufficiency.
Topics: Analysis of Variance; Animals; Cardiac Output; Disease Models, Animal; Hyperuricemia; Male; Mesenter | 2015 |
[Regulatory effect of leonurus extracts on hyperuricemia in rats].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Down-Regulation; Gene | 2014 |
Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension.
Topics: Adenosine Triphosphate; Allopurinol; Animals; Antioxidants; Blood Pressure; Cyclic N-Oxides; Disease | 2015 |
Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice.
Topics: Allopurinol; Animals; Creatinine; Disease Models, Animal; Drug Synergism; Glucose Transport Proteins | 2015 |
[The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice].
Topics: Administration, Oral; Animals; Biological Products; Biomarkers; Blood Pressure; Bombyx; Chromatograp | 2015 |
Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Antioxidants; Disease Models, Animal; Gout Suppressants; Hyperuricemia; Kidney; Male; Mice; | 2015 |
Melamine Nephrotoxicity is Mediated by Hyperuricemia.
Topics: Animals; Disease Models, Animal; Hyperuricemia; Kidney Diseases; Lipid Peroxidation; Male; Oxonic Ac | 2015 |
Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
Topics: Administration, Oral; Animals; Biomarkers; Biotransformation; Disease Models, Animal; Dose-Response | 2016 |
Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
Topics: Animals; Biomarkers; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Et | 2016 |
Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Disease Models | 2017 |
Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzym | 2017 |
Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.
Topics: Aldosterone; Animal Feed; Animals; Autoradiography; Blood Pressure; Disease Models, Animal; Hyperten | 2008 |
Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzofurans; Depsid | 2008 |
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.
Topics: Aldehydes; Angiotensin II; Animals; Antioxidants; Arterioles; Body Weight; Cyclic N-Oxides; Disease | 2008 |
Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Angiotensins; Animals; Cells, Cultured; Disease Models | 2008 |
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Transformed; Cell Prolife | 2010 |
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2010 |
[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Drug Com | 2010 |
Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats.
Topics: Allopurinol; Animals; Aorta; Arginine; Benzbromarone; Biological Transport; Blood Pressure; Cationic | 2011 |
Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice.
Topics: Allopurinol; Animals; Anthocyanins; Disease Models, Animal; Hyperuricemia; Ipomoea batatas; Male; Mi | 2011 |
Hypouricemic effect of the methanol extract from Prunus mume fruit in mice.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fruit; Hype | 2012 |
Reducing effect of mangiferin on serum uric acid levels in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gout; | 2012 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cisplatin; Disease Models, Animal; Drug Combinations | 2002 |
Mild hyperuricemia induces glomerular hypertension in normal rats.
Topics: Animals; Arterioles; Blood Pressure; Disease Models, Animal; Hypertension, Renal; Hypertrophy; Kidne | 2002 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
Topics: Allopurinol; Animals; Antioxidants; Biflavonoids; Catechin; Disease Models, Animal; Dose-Response Re | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disea | 2004 |
[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats].
Topics: Animals; Anti-Infective Agents; Brazil; Caffeic Acids; China; Coumaric Acids; Disease Models, Animal | 2005 |
Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats.
Topics: Administration, Oral; Allopurinol; Animals; Chrysanthemum; Disease Models, Animal; Dose-Response Rel | 2005 |
Effect and mechanism of total saponin of Dioscorea on animal experimental hyperuricemia.
Topics: Animals; Dioscorea; Disease Models, Animal; Hyperuricemia; Injections, Intraperitoneal; Liver; Male; | 2006 |
[Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Models, | 2007 |
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Topics: Animals; Disease Models, Animal; Febuxostat; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; M | 2008 |
Renal function in rats with acute medullary injury.
Topics: Acute Kidney Injury; Animals; Calcium; Diet; Disease Models, Animal; Glomerular Filtration Rate; Hyd | 1980 |
Hypouricemic and uricosuric actions of AA-193 in a hyperuricemic rat model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Isoxazoles; Kidney; Liver; Male; | 1994 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin | 1999 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
[Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2002 |
Physiological characteristics of various experimental models for the study of disorders in purine metabolism.
Topics: Acidosis; Alkalosis; Allopurinol; Animals; Cholesterol; Disease Models, Animal; Diuresis; Fructose; | 1977 |
High steady-state levels of uric acid produced in rats by dietary training and potassium oxonate.
Topics: Animals; Diet; Disease Models, Animal; Feeding Behavior; Male; Oxonic Acid; Rats; Time Factors; Tria | 1979 |
Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
Topics: Animals; Diet; Disease Models, Animal; Female; Fusarium; Gout; Nucleic Acids; Oxonic Acid; Platelet | 1976 |
Chronic experimental hyperuricemic nephropathy.
Topics: Animals; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Nephritis, Interstitial; Oxonic Acid; | 1975 |